Telbivudine-induced rhabdomyolysis in a patient undergoing haemodialysis: A case report and review of literature

J Int Med Res. 2023 Dec;51(12):3000605231222244. doi: 10.1177/03000605231222244.

Abstract

Herein, we describe a case of acute rhabdomyolysis in a man in his early 50s undergoing haemodialysis and receiving the antiviral drug, telbivudine, for chronic hepatitis B virus (HBV) infection. Following diagnosis by electromyography (EMG), magnetic resonance image (MRI) scans and laboratory data (i.e., elevated serum creatinine kinase (CK) and myoglobin) telbivudine was discontinued and the patient was treated with methylprednisolone. While his CK and myoglobin levels decreased rapidly, his muscle weakness and pain improved slowly. Learning points include: patients undergoing haemodialysis and concomitantly receiving antiviral treatment for HBV, should have their serum levels of CK and myoglobin monitored regularly; treatment with corticosteroids maybe required; relief from rhabdomyolysis-induced muscle weakness and pain may be slow due to nerve fibre damage.

Keywords: Haemodialysis; Hepatitis B virus; Telbivudine; rhabdomyolysis.

Publication types

  • Review
  • Case Reports

MeSH terms

  • Antiviral Agents / adverse effects
  • Hepatitis B, Chronic* / complications
  • Hepatitis B, Chronic* / drug therapy
  • Humans
  • Male
  • Muscle Weakness
  • Myoglobin / adverse effects
  • Pain / drug therapy
  • Renal Dialysis
  • Rhabdomyolysis* / chemically induced
  • Rhabdomyolysis* / drug therapy
  • Telbivudine / adverse effects
  • Thymidine / adverse effects

Substances

  • Telbivudine
  • Antiviral Agents
  • Myoglobin
  • Thymidine